Solid-State Characterization and Transformation of Various Creatine Phosphate Sodium Hydrates

被引:21
作者
Xu, Yun [1 ]
Jiang, Linglei [1 ]
Huang, Ying [1 ]
Wang, Jian-Rong [1 ]
Mei, Xuefeng [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Pharmaceut Analyt & Solid State Chem Res Ctr, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
creatine phosphate sodium; hydrates; crystal structure; physical characterization; stability; form transformation; INORGANIC-PHOSPHATE; CRYSTAL-STRUCTURE; WATER ACTIVITY; FORM; DRUG; CARBAMAZEPINE; THEOPHYLLINE; POLYMORPHISM; CONVERSION; STABILITY;
D O I
10.1002/jps.24175
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Creatine phosphate sodium (CPS) salt is a first-line cardiovascular drug for severe diastolic heart failure. The drug exists in different hydrate forms. The marketed drug form was determined as CPS4.5H(2)O (H1); however, the reference standard was supplied as CPS6H(2)O (H2). In this work, we present two newly identified hydrate forms: a thermodynamically stable low hydrate form, CPS1.5H(2)O (H3), and a pressure-sensitive transit form, CPS7H(2)O (H4). The hydrate forms were discovered through a comprehensive solid-state screening experiment and fully characterized using a range of analytical techniques including X-ray powder diffraction (XRPD), FTIR, Raman spectroscopy, hot-stage microscopy (HSM), thermogravimetric analysis, and differential scanning calorimetry. Stability tests revealed that H3 was the most stable hydrate under thermal stimulation. H4 is a pressure-sensitive hydrate and easily transforms to H2 and then H1 upon grinding. The form transformation process was closely monitored using the HSM, variable-temperature XRPD (VT-XRPD), and VT-Raman spectroscopy techniques. Specifically, the transformation of H4 to H1 is characterized in a single-crystal-to-single-crystal transformation process. The newly discovered hydrate form H3 has superior physicochemical properties than the marketed forms and is worthy of further development. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3688-3695, 2014
引用
收藏
页码:3688 / 3695
页数:8
相关论文
共 40 条
[31]   A short history of SHELX [J].
Sheldrick, George M. .
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2008, 64 :112-122
[32]   Temperature-Dependent Hydration/Dehydration Behavior of Poly(ethylene oxide)s in Aqueous Solution [J].
Shikata, Toshiyuki ;
Okuzono, Misumi ;
Sugimoto, Natsuki .
MACROMOLECULES, 2013, 46 (05) :1956-1961
[33]   Drug polymorphism and dosage form design: a practical perspective [J].
Singhal, D ;
Curatolo, W .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (03) :335-347
[34]  
Sivakumar B, 2012, J CHEM PHARM RES, V4, P4589
[35]   Structure and physical stability of hydrates and thermotropic mesophase of calcium benzoate [J].
Terakita, A ;
Byrn, SR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (05) :1162-1172
[36]   Insight into Crystallization Mechanisms of Polymorphic Hydrate Systems [J].
Tian, Fang ;
Qu, Haiyan ;
Louhi-Kultanen, Marjatta ;
Rantanen, Jukka .
CHEMICAL ENGINEERING & TECHNOLOGY, 2010, 33 (05) :833-838
[37]   Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model drug [J].
Ticehurst, MD ;
Storey, RA ;
Watt, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 247 (1-2) :1-10
[38]   Pharmacokinetics of Carbamazepine Polymorphs and Dihydrate in Rats, Related to Dogs and Humans [J].
Xu, Caihong ;
Zou, Meijuan ;
Liu, Yi ;
Ren, Jungang ;
Tian, Ye ;
Yan, Jing ;
Wang, Yiping ;
Cheng, Gang .
ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (11) :1973-1982
[39]   Contrasting the Surface and Bulk Properties of Anhydrate and Dehydrated Hydrate Materials [J].
Yamauchi, Masahiro ;
Lee, Eun Hee ;
Otte, Andrew ;
Byrn, Stephen R. ;
Carvajal, M. Teresa .
CRYSTAL GROWTH & DESIGN, 2011, 11 (03) :692-698
[40]   Influence of water activity in organic solvent plus water mixtures on the nature of the crystallizing drug phase .1. Theophylline [J].
Zhu, HJ ;
Yuen, CM ;
Grant, DJW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 135 (1-2) :151-160